Rallybio Corporation (RLYB)

CIK 0001739410 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 —
Q1-2026 —
Latest FY-2025 —
Q3-2025 8-K (2025-11-06) · 99.1
Q2-2025 8-K (2025-08-07) · 99.1
Q1-2025 8-K (2025-05-08) · 99.1
FY-2024 8-K (2025-03-13) · 99.1
Q3-2024 8-K (2024-11-07) · 99.1
Q2-2024 8-K (2024-08-08) · 99.1
Q1-2024 8-K (2024-05-09) · 99.1
FY-2023 8-K (2024-03-12) · 99.1  |  8-K (2024-02-06) · 99.1
Q3-2023 8-K (2023-11-09) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Condensed Consolidated Statements of Operations and Comprehensive Income (loss)
—
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Changes In Stockholders' Equity
Consolidated Statements of Cash Flows
Consolidated Statements of Changes In Stockholders' Equity (P)
Consolidated Statements of Cash Flows (P)
—
Notes
Balance Sheet Components
Business
—
Business and Liquidity
—
Collaboration and License Agreements
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Income Taxes
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Investment In Joint Venture
Leases
—
License and Collaboration Agreements
—
Marketable Securities
Net Income (loss) Per Common Share
—
Net Loss Per Common Share
Pay Vs Performance Disclosure
Restructuring
Restructuring and Severance
—
Segments
Stockholders' Equity
Subsequent Events
Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation